UY35402A - ?compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis?. - Google Patents

?compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis?.

Info

Publication number
UY35402A
UY35402A UY0001035402A UY35402A UY35402A UY 35402 A UY35402 A UY 35402A UY 0001035402 A UY0001035402 A UY 0001035402A UY 35402 A UY35402 A UY 35402A UY 35402 A UY35402 A UY 35402A
Authority
UY
Uruguay
Prior art keywords
fibrosis
alkenyl
alkyl
treatment
aromatic compounds
Prior art date
Application number
UY0001035402A
Other languages
English (en)
Spanish (es)
Inventor
Gagnon Lyne
Laurin Pierre
Grouix Brigitte
Zacharie Boulos
Abbott Shaun
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of UY35402A publication Critical patent/UY35402A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
UY0001035402A 2013-03-15 2014-03-13 ?compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis?. UY35402A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361798269P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
UY35402A true UY35402A (es) 2014-10-31

Family

ID=51535669

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035402A UY35402A (es) 2013-03-15 2014-03-13 ?compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis?.

Country Status (25)

Country Link
US (3) US10023518B2 (enExample)
EP (1) EP2970089B1 (enExample)
JP (1) JP6448562B2 (enExample)
KR (1) KR102196721B1 (enExample)
CN (2) CN110105200B (enExample)
AR (1) AR095429A1 (enExample)
AU (1) AU2014231648B2 (enExample)
BR (1) BR112015022008A2 (enExample)
CA (1) CA2905621C (enExample)
CL (1) CL2015002535A1 (enExample)
DK (1) DK2970089T3 (enExample)
EA (1) EA030651B1 (enExample)
ES (1) ES2741439T3 (enExample)
IL (1) IL241178B (enExample)
MX (1) MX379424B (enExample)
MY (1) MY180305A (enExample)
NZ (1) NZ712797A (enExample)
PH (1) PH12015502011B1 (enExample)
PL (1) PL2970089T3 (enExample)
PT (1) PT2970089T (enExample)
SG (1) SG11201507408XA (enExample)
TW (1) TWI689490B (enExample)
UY (1) UY35402A (enExample)
WO (1) WO2014138906A1 (enExample)
ZA (1) ZA201507061B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
US9200004B2 (en) 2013-01-15 2015-12-01 Incyte Holdings Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
TWI689489B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
EP3203998B1 (en) * 2014-10-10 2021-03-10 Liminal Biosciences Limited Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
MY194308A (en) 2014-10-10 2022-11-27 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compostions for the prevention and treatment of osteoporosis
JP6720169B2 (ja) * 2014-11-12 2020-07-08 リミナル・バイオサイエンシーズ・リミテッドＬｉｍｉｎａｌ ＢｉｏＳｃｉｅｎｃｅｓ Ｌｉｍｉｔｅｄ 組織の自己修復及び再生のための置換芳香族化合物及び医薬組成物
SG11201707555RA (en) * 2015-03-18 2017-10-30 Vectus Biosystems Ltd Compositions for the treatment of kidney and/or liver disease
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US20190144547A1 (en) * 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
US10463645B2 (en) * 2016-05-19 2019-11-05 Everfront Biotech Inc. Method for delaying the onset of pulmonary fibrosis or treating pulmonary fibrosis
TWI684459B (zh) 2016-12-15 2020-02-11 大陸商深圳瑞健生命科學研究院有限公司 一種治療動脈粥樣硬化及其併發症的方法
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
KR102126389B1 (ko) * 2018-09-14 2020-06-25 셀라이온바이오메드 주식회사 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물
AU2019358595B2 (en) 2018-10-11 2025-04-17 Basf As Aromatic compounds and pharmaceutical uses thereof
IL302014A (en) * 2020-10-06 2023-06-01 Pharmaceutique Ingenew Inc Substituted aromatic compounds and pharmaceutical compositions thereof
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183519A1 (en) * 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
BRPI0711228A2 (pt) * 2006-05-26 2012-06-19 Auspex Pharmaceuticals Inc "composto, método de tratar um mamìfero que sofre de um doença ou de uma condição envolvendo as enzimas ciclooxiganase, composição farmacêutica, processo para e deuteração de um composto pelatroca de pelomenos um átomo de hidrogênio do dito composto com um átomo do deutério e processo para preparar m composto"
CN101616583A (zh) * 2007-02-08 2009-12-30 爱密斯菲尔科技公司 苯烷基羧酸输送剂
JP2012526052A (ja) * 2009-05-04 2012-10-25 プロメティック・バイオサイエンシーズ・インコーポレイテッド 置換芳香族化合物およびその薬学的使用
DK2427417T3 (da) * 2009-05-04 2014-01-20 Prometic Biosciences Inc Salte af 3-pentylphenyleddikesyre og farmaceutiske anvendelser deraf
AT509045B1 (de) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale

Also Published As

Publication number Publication date
CN110105200B (zh) 2022-04-12
AU2014231648B2 (en) 2018-02-08
AR095429A1 (es) 2015-10-14
EA201591775A1 (ru) 2016-05-31
KR20160051676A (ko) 2016-05-11
CA2905621C (en) 2021-06-29
MY180305A (en) 2020-11-27
DK2970089T3 (da) 2019-08-05
TW201441186A (zh) 2014-11-01
ZA201507061B (en) 2017-03-26
US20180237374A1 (en) 2018-08-23
US10023518B2 (en) 2018-07-17
KR102196721B1 (ko) 2020-12-30
CN105189438A (zh) 2015-12-23
US20200172462A1 (en) 2020-06-04
US11524930B2 (en) 2022-12-13
BR112015022008A2 (pt) 2021-05-25
PH12015502011B1 (en) 2020-12-04
US10550066B2 (en) 2020-02-04
EP2970089A1 (en) 2016-01-20
IL241178B (en) 2020-09-30
PL2970089T3 (pl) 2020-01-31
MX379424B (es) 2025-03-11
WO2014138906A1 (en) 2014-09-18
CN110105200A (zh) 2019-08-09
JP2016512202A (ja) 2016-04-25
EA030651B1 (ru) 2018-09-28
PT2970089T (pt) 2019-09-04
SG11201507408XA (en) 2015-10-29
ES2741439T3 (es) 2020-02-11
IL241178A0 (en) 2015-11-30
PH12015502011A1 (en) 2016-01-11
AU2014231648A1 (en) 2015-10-22
MX2015011878A (es) 2016-06-07
CA2905621A1 (en) 2014-09-18
US20160039736A1 (en) 2016-02-11
EP2970089B1 (en) 2019-05-08
TWI689490B (zh) 2020-04-01
EP2970089A4 (en) 2016-10-12
CL2015002535A1 (es) 2016-03-28
NZ712797A (en) 2020-08-28
JP6448562B2 (ja) 2019-01-09
HK1220440A1 (en) 2017-05-05

Similar Documents

Publication Publication Date Title
UY35402A (es) ?compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis?.
UY35401A (es) ?compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca?.
CL2022000619A1 (es) Oxinitruro de piridina, método para su preparación y uso de este
CL2020001090A1 (es) Compuesto de pirimidina como inhibidor de las janocinasas.
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
AR071788A1 (es) Derivados de 3-aminocarbazol, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos para tratar y/o prevenir trastornos asociados con la produccion de prostaglandina e2(pge2), tales como aterosclerosis, artritis, artrosis y tumores, entre otros.
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
MX2018000179A (es) Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
UY36207A (es) Inhibidores de la syk
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
DOP2014000133A (es) Triazolopiridinas sustituidas
AR107828A1 (es) 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k
PE20200698A1 (es) Gel que comprende clorhexidina
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
PE20200341A1 (es) Composiciones y compuestos terapeuticos y metodos para utilizarlos
JOP20200024A1 (ar) مركبات ثنائي هيدروكساديازينون
BR112016025126A2 (pt) formulação líquida compreendendo composto neutralizante de gm-csf
BR112017020081A2 (pt) análogos deuterados de etifoxina, seus derivados e usos dos mesmos
AR102246A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos
MX2017004738A (es) Compuestos aromaticos sustituidos y composiciones farmaceuticas para la prevencion y tratamiento de la diabetes.
AR084446A1 (es) Derivados de bifenilo y su uso en el tratamiento de enfermedades de la piel y de la cavidad bucal
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento
DOP2017000138A (es) Derivados de fumagilol

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220817